These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27267463)

  • 1. Under-representation of frail older people in meta-analysis of dipeptidyl peptidase-4 inhibitors and hypoglycaemia.
    Tufan F; Soyluk O; Bahat G; Karan MA
    BMJ; 2016 Jun; 353():i3183. PubMed ID: 27267463
    [No Abstract]   [Full Text] [Related]  

  • 2. Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia.
    Boucaud-Maitre D
    BMJ; 2016 Jun; 353():i3186. PubMed ID: 27267596
    [No Abstract]   [Full Text] [Related]  

  • 3. Authors' reply to Tufan and colleagues and Boucaud-Maitre.
    Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
    BMJ; 2016 Jun; 353():i3188. PubMed ID: 27267359
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Kundu A; Sardar P; Ghosh S; Patel P; Chatterjee S; Meyer TE
    Int J Cardiol; 2016 Jun; 212():203-5. PubMed ID: 27043061
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
    Frandsen CS; Madsbad S
    Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes].
    Jojima T; Aso Y
    Nihon Rinsho; 2013 Nov; 71(11):1987-92. PubMed ID: 24397171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 8. [Dipeptidyl peptidase-4 inhibitors in type 2 diabetic elderly patient].
    Doucet J; Bauduceau B; Blicklé JF
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):157-62. PubMed ID: 21690023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial pneumonia during administration of dipeptidyl peptidase-4 inhibitors.
    Tagaya Y; Okada S; Hisada T; Niijima Y; Yamada M
    J Diabetes; 2016 May; 8(3):442. PubMed ID: 26678559
    [No Abstract]   [Full Text] [Related]  

  • 10. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C; Bollaerts K
    Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes.
    Patel T; Tesfaldet B; Gandotra C;
    BMJ; 2016 May; 353():i2920. PubMed ID: 27220716
    [No Abstract]   [Full Text] [Related]  

  • 13. [Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas].
    Mukai E; Fujimoto S; Inagaki N
    Nihon Rinsho; 2011 May; 69(5):907-11. PubMed ID: 21595280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Saf; 2015 Apr; 14(4):505-24. PubMed ID: 25630605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB
    Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
    Tanaka K; Ogawa Y; Shimada S
    J Dermatol; 2012 Aug; 39(8):726-8. PubMed ID: 21981936
    [No Abstract]   [Full Text] [Related]  

  • 17. Joint pain linked to diabetes drugs.
    Health After 50 Sci Am Consum Health; 2016 Jan; 27(12):6. PubMed ID: 27062738
    [No Abstract]   [Full Text] [Related]  

  • 18. The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin.
    Hamasaki H; Yanai H
    Int J Cardiol; 2013 Oct; 168(3):e106. PubMed ID: 23972359
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
    Halimi S; Raccah D; Schweizer A; Dejager S
    Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin for Type 2 diabetes: a 2015 update.
    Lee M; Rhee MK
    Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):597-610. PubMed ID: 26000559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.